This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chester, S. J. Articles by Albala, M. M. Search for Related Content PubMed PubMed Citation Articles by Chester, S. J. Articles by Albala, M. M.

Treatment of an Established Graft-versus-Host Reaction in AKR Mice by Adoptive Immunotherapy¹

Division of Clinical Hematology, Department of Medicine [S. J. C., M. M. A.], and Department of Pathology [A. R. E.], Rhode Island Hospital, Providence, Rhode Island 02902

A model system in AKR mice for the induction and cure of a clinically evident graft-versus-host disease is reported. Graft-versus-host disease is initiated by i.p. injections of cyclophosphamide (250 mg/kg body weight) into female AKR mice, on Day 0. This is followed by i.v. injections of 45 x 10⁶ normal spleen cells (NSC) from male C57BL/6J mice. Median survival time for these mice is 33.4 ± 4.5 days.

Following the administration of C57BL/6J NSC, AKR mice were rescued from graft-versus-host disease by the following treatment protocol: (a) Day 6, 35 x 10⁶ DBA/2 NSC given i.v.; (b) Day 10, cyclophosphamide i.p. (150 mg/kg body weight); (c) Days 11 and 16, 35 x 10⁶ AKR NSC given i.v.

These experiments demonstrate that graft-versus-host reaction can be eliminated by coupling a graft-versus-host reaction with a graft-versus-graft reaction and restoring the host by immunocompetent syngeneic cells.

¹ First article of a series. This research was supported in part by the George V. Meehan Fund-Clinical Research in Blood Diseases, The Phyllis Kimball Johnstone and H. Earle Kimball Foundation, and the Louis and Goldie Chester Memorial Fund.

Received 7/ 2/74. Accepted 11/18/74.